R&D channel feed

Gilead­'s Kite earns sec­ond-line win for CAR-T Yescar­ta, set­ting up a bat­tle over ear­li­er blood can­cer pa­tients

4 years ago
Pharma
Cell/Gene Tx

Ex­elix­is posts mixed re­sults for Cabome­tyx com­bo in ear­ly liv­er can­cer pa­tients, cast­ing doubt on piv­otal read­out

4 years ago

Sanofi, As­traZeneca mark big leap to­ward fil­ing of RSV drug in 2022, with safe­ty da­ta in hand to chal­lenge Synagis

4 years ago

Polyphor mulls fu­ture af­ter PhI­II can­cer pro­gram crash­es

4 years ago

Hit­ting land­mark mile­stone, In­tel­lia shows CRISPR can ed­it genes di­rect­ly in pa­tients

4 years ago
Cell/Gene Tx

Af­ter years of fail­ure, Vi­a­Cyte shows off first proof-of-con­cept for di­a­betes stem cell trans­plants

4 years ago

FDA push­es back de­ci­sions on Ab­b­Vie's Rin­voq sNDAs to fur­ther re­view a failed Pfiz­er tri­al

4 years ago
FDA+

Covid-19 roundup: Pieris to in­ves­ti­gate treat­ment of long Covid with Bavar­i­an grant mon­ey; A roller­coast­er year ends in FDA OK for re­pur­posed Covid drug

4 years ago
Coronavirus

An­oth­er Cor­bus pro­gram hits the skids af­ter late-stage flop, plum­met­ing the small biotech's shares

4 years ago

FDA en­cour­ages in­clud­ing in­cur­able can­cer pa­tients in tri­als, re­gard­less of pri­or ther­a­pies

4 years ago
FDA+

Sen­a­tors call for hear­ing to ex­am­ine how Medicare will han­dle Bio­gen's new Alzheimer's drug

4 years ago
FDA+

Ar­cus de­clares cryp­tic in­ter­im win for close­ly watched an­ti-TIG­IT drug, but you'll have to wait for the da­ta

4 years ago

Neu­rona Ther­a­peu­tics is dash­ing to the clin­ic with its cell ther­a­py for epilep­sy — but first, an­oth­er ven­ture round

4 years ago
Financing

Mer­ck­'s Keytru­da blazes a path in first-line cer­vi­cal can­cer, mak­ing good on drug­mak­er's push for ear­li­er pa­tients

4 years ago
Pharma

No­var­tis bur­nish­es Zol­gens­ma da­ta in presymp­to­matic pa­tients as Roche's Evrys­di con­tin­ues eat­ing away at the SMA pie

4 years ago

Tar­sus nabs key da­ta in hunt to re­pur­pose dog drug as cure for eye par­a­site

4 years ago

Who are the lu­mi­nar­ies dri­ving the biggest ad­vances in bio­phar­ma R&D? End­points News is ask­ing for your nom­i­na­tions for a spe­cial re­port

4 years ago

Biotech founder placed on leave as $400M Alzheimer's start­up idea comes un­der scruti­ny

4 years ago
People

Sid Mukher­jee's Vor adds clin­i­cal man­u­fac­tur­ing fa­cil­i­ty at ex­ist­ing Boston-area site, beef­ing up for a com­mer­cial push

4 years ago
Manufacturing

Blue­print Med­i­cines nabs 4th ap­proval in bid to­ward prof­itabil­i­ty

4 years ago

Cure­Vac blames vari­ants as a close­ly-watched Covid vac­cine goes down in flames, fail­ing piv­otal study with woe­ful da­ta

5 years ago

Days af­ter con­tro­ver­sy greet­ed Bio­gen's block­buster Alzheimer's OK, the big biotech con­cedes a set­back on the tau front

5 years ago

In a first, Re­gen­eron's an­ti­body cock­tail re­duces deaths for a sub­group of hos­pi­tal­ized Covid-19 pa­tients

5 years ago
Coronavirus

As­traZeneca's Covid-19 an­ti­body cock­tail miss­es the mark in pre­vent­ing symp­toms post-ex­po­sure

5 years ago
Coronavirus
First page Previous page 166167168169170171172 Next page Last page
A service from the Financial Times